Do Son 
At the recently held Apple “Awe Dropping” Fall Event, Apple unveiled a groundbreaking feature for the Apple Watch Series 11—algorithm-driven Hypertension Alerts—a function that has already received approval from the U.S. Food and Drug Administration (FDA). Beginning September 19, this feature will be activated globally across 150 countries and regions, coinciding with the launch of the Apple Watch Series 11 and the Apple Watch Ultra 3 in the United States and other markets.
Unlike traditional cuff-based blood pressure monitors, the Apple Watch Series 11 leverages its built-in optical heart rate sensor to gather data, which is then processed through a newly developed machine learning algorithm. This algorithm, designed to run passively in the background for about a month, analyzes fluctuations and patterns in the wearer’s heart rate to assess potential hypertension risks. If abnormal trends are detected, the system issues an alert urging the user to seek medical consultation before the condition escalates.
Apple emphasized that this feature does not provide instantaneous blood pressure readings. Instead, it offers early warnings of possible hypertension, allowing proactive action before the onset of severe complications. The underlying model is trained on clinical data from over 100,000 participants, meeting the FDA’s stringent accuracy standards.
In recent years, Apple has increasingly positioned the Apple Watch as a pivotal tool in preventive healthcare. Beyond its well-known capabilities such as heart rate tracking, atrial fibrillation detection, and fall alerts, the company secured FDA approval last year to enable second-generation AirPods Pro to function as over-the-counter hearing aids, while also introducing sleep apnea detection to watchOS. With the green light for Hypertension Alerts, Apple now addresses another chronic health risk—high blood pressure—which affects over a billion people worldwide.
That said, Apple’s health technology ambitions are not without challenges. Its blood oxygen monitoring feature remains entangled in an ongoing patent dispute with Masimo. Nevertheless, Apple continues to press forward, signaling that health innovation is a cornerstone of its long-term strategy. Industry speculation persists about the company’s eventual rollout of additional physiological monitoring tools, including the long-rumored non-invasive glucose tracking.
With FDA approval secured, Apple will activate Hypertension Alerts across 150 global markets, elevating the Apple Watch Series 11 from a mere wearable device into a frontline companion for daily health management.
The key question moving forward is whether this type of non-real-time blood pressure monitoring will successfully increase early diagnosis rates for hypertension—and whether it will spark a new wave of competition among wearable manufacturers racing to expand their health monitoring ecosystems.
Related Posts:
- Apple Watch Series 11: A New Era of Health and Connectivity
- Ransomware Gangs’ New Tactic: Weaponizing Legitimate Entities
- Apple Restores Blood Oxygen Feature to Apple Watch in U.S. After Patent Dispute
- Cybercriminals Target OneBlood: Blood Supply Chain Threatened
Support Our Threat Intelligence
If you find our CVE report and cybersecurity news helpful, consider supporting our work.
Buy Me a Coffee
PayPal
